UGT1A1 and neutropenia: Another meta-analysis consisting of 1998 patients suggested that a dose-dependent association existed between homozygous UGT1A1*28 patients and the risk of irinotecan-induced neutropenia with the high dose (≥ 250 mg/m2) compared to the low (80–145 mg/m2) and medium (150–200 mg/m2) doses (relative risk: 7.22 vs. 2.04) [24].